Breaking ground with a novel first line dry eye therapy
March 11, 2022 12:00 pmBased on the IntelliGel platform which delivers moisturizing water and protection for the eye, RP501 is Redwood Pharma’s developmental hydrogel... View Article
Based on the IntelliGel platform which delivers moisturizing water and protection for the eye, RP501 is Redwood Pharma’s developmental hydrogel... View Article
NASDAQ FIRST NORTH GROWTH MARKET: REDW.ST, redwoodpharma.se 1 January – 31 December 2021 The company’s net revenue for the period... View Article
NASDAQ FIRST NORTH GROWTH MARKET:REDW.ST, REDWOODPHARMA.SE Perioden 1 januari – 31 december 2021 Bolagets nettoomsättning för perioden uppgick till 0... View Article
Redwood Pharma has received approval from an Austrian ethics committee for the start of a clinical trial of RP501. This... View Article
Redwood Pharma har erhållit godkännande från den österrikiska etikkommittén att starta en klinisk prövning av RP501. Ansökan utgör det första... View Article
Redwood Pharma will be attending two of the leading international conferences in ophthalmology and biotechology during 2022. The goals of... View Article
Redwood Pharma will be attending two of the leading international conferences in ophthalmology and biotechology during 2022. The goals of... View Article
Redwood Pharma extends its reach into the medical technology arena with the broadening of its development programs with the RP501... View Article